4BIO Capital
VC Fund
London, United Kingdom
4BIO Capital is a VC fund in London focused on Biotechnology and Health Care. 4BIO Ventures is a London-based firm investing in venture capital and public equities in life sciences. They are focused on advanced therapies addressing high unmet medical and social needs.4BIO Capital Partners is an emerging asset manager focusing on private equity and venture capital in high growth and high return segments of biotech -biologics, gene and cell therapy and bioinformatics.
- Total investments:
- 32
- Last investment:
- Lead investor:
- 44%
- Fund size:
- $50M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries 4BIO Capital invests in
Stages 4BIO Capital invests in
Countries 4BIO Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $5M–$19M
- Series A
- $24M–$94M
- Series B
- $12M–$125M
Investment Focus
Industry
- Biotechnology 15 (47%)
- Health Care 9 (28%)
- Therapeutics 9 (28%)
- Medical 8 (25%)
- Life Science 5 (16%)
Stage
- Series A 10 (31%)
- Seed 5 (16%)
- Series B 4 (13%)
- Post-IPO Equity 3 (9%)
- Series C 2 (6%)
Country
- United States 7 (22%)
- United Kingdom 7 (22%)
- France 2 (6%)
- Switzerland 2 (6%)
- Japan 1 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Andrew Kozlov
Managing Partner
|
Managing Partner | Total investments: 2 | Find email | |
Dmitry Kuzmin
Managing Partner
|
Managing Partner | Total investments: 8 | Find email | |
Kieran Mudryy
Partner
|
Partner | Total investments: 1 | Find email | |
Owen Smith
Principal
|
Principal | Total investments: 7 | Find email | |
Vasily Fedorin
Principal
|
Principal | Total investments: 0 | Find email | |
| See all 6 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Cytospire Therapeutics
|
Cytospire Therapeutics is bringing forward a portfolio of next generation immune cell engagers. | $82.6M / Series A / May 05, 2026 | |
Ray Therapeutics
|
Ray Therapeutics is a biotech company developing optogenetic gene therapies for patients with blinding diseases. | $125M / Series B / Apr 21, 2026 | |
Trogenix
|
Trogenix operates as a therapeutics company, that treats aggressive cancers. | $94.4M / Series A / Oct 06, 2025 | |
Actithera
|
Actithera is a molecular radiotherapeutic company that develops radioligand therapies. It translates medicinal chemistry insights into new radioligand therapies (RLTs) and applies various molecular design strategies, including covalent targeting and an isotope-agnostic philosophy, to invent RLTs with significant differentiation and largertherapeutic windows. | $75.5M / Series A / Jul 09, 2025 | |
March Biosciences
|
March Biosciences is a clinical-stage cell therapy company that focuses on developing CAR-T cell strategies to address hematological cancers. | $28.4M / Series A / Oct 23, 2024 | |
Hornet Therapeutics
|
Hornet Therapeutics provides immune cell metabolism & cell therapy for cancer treatment. | $5M / Seed / May 23, 2024 | |
|
Trogenix
|
Trogenix operates as a therapeutics company, that treats aggressive cancers. | $19.1M / Seed / Jan 01, 2024 | |
ViaNautis
|
Precision Solutions | $24.6M / Series A / Nov 13, 2023 | |
|
Ray Therapeutics
|
Ray Therapeutics is a biotech company developing optogenetic gene therapies for patients with blinding diseases. | $100M / Series A / May 16, 2023 | |
Ascend Gene & Cell Therapies
|
Ascend Gene & Cell Therapies supports manufacturing and process development projects from design through to clinical and commercial scales. They partner with biotechnology teams to embed scalable manufacturing in their operations from the beginning. They respond to customer inquiries by phone and contact form. | $65.9M / Series A / Mar 20, 2023 | |
| See all 32 investments → | |||
Co-Investors
Abingworth
7 deals together
Fast Track Initiative, Inc.
6 deals together
Nippon Venture Capital
6 deals together
MRL Ventures Fund
5 deals together
UPMC Enterprises
5 deals together
DCVC Bio
4 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does 4BIO Capital invest in?
4BIO Capital invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Seed stage. Most of the 32 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is 4BIO Capital's check size?
4BIO Capital typically joins rounds of $5M–$19M at Seed, $24M–$94M at Series A and $12M–$125M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds 4BIO Capital participates in.
How do I contact 4BIO Capital?
Public channels for 4BIO Capital include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at 4BIO Capital?
The team at 4BIO Capital includes Andrew Kozlov (Managing Partner), Dmitry Kuzmin (Managing Partner) and Kieran Mudryy (Partner), among 6 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
